Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
Where are the drugs and diagnostics to tackle this global health crisis?
Virtually no research into TB drugs has been carried out since the 1960s. Once the disease was effectively eradicated in wealthy countries, pharmaceutical companies lost interest in developing new products. With no market incentive in developing drugs for people in poorer countries unable to afford their high prices, research activity slowed to a standstill.
Mapping the gaps in research and development
In order to focus attention on the desperate lack of medical tools to tackle TB, MSF produced an analysis of research currently underway into drugs and diagnostics for TB, highlighting the gaps where work needs to be done.
After 40 years of inactivity, new compounds are now under investigation. But there are still far too few candidates that are likely to make it through to the final stage. The advances made in basic scientific knowledge of the bacterium that causes TB are only very slowly being translated into drugs necessary to revolutionise TB treatment and curb the epidemic. A parallel report examining current diagnostics research revealed even fewer promising developments suited to the settings where we work.
Read more
MSF's analysis of TB drug development pipeline 
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
